Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study

International Journal of Clinical Oncology

Volumn 20, Issue 1, 2015, Pages 111-116

  Matsumoto, Toshihiko ^a   Nishina, Tomohiro ^a   Mizuta, Minoru ^b   Tsuji, Akihito ^c,i   Watanabe, Ryouhei ^d   Takahashi, Ikuo ^e   Watanabe, Yuji ^f   Moriwaki, Toshikazu ^g   Maeba, Takashi ^h   Hyodo, Ichinosuke ^g  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b Mitoyo General Hospital   (Japan)

^c Kochi Health Sciences Center   (Japan)

^d MATSUYAMA SHIMIN HOSPITAL   (Japan)

^e MATSUYAMA RED CROSS HOSPITAL   (Japan)

^f EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF TSUKUBA   (Japan)

^h Social Insurance Ritsurin Hospital   (Japan)

ⁱ KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

Chemotherapy; Elderly patients; Metastatic colorectal cancer; UFT

Indexed keywords

ANTINEOPLASTIC AGENT; FOLINIC ACID; TEGAFUR; URACIL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUCOVORIN; MALE; TEGAFUR; URACIL;

EID: 84893823483     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-014-0675-5     Document Type: Article

References (22)

1. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917
2. Gallego R, Sanchez N, Maurel J (2006) Chemotherapy for elderly patients with advanced colorectal carcinoma. Expert Rev Anticancer Ther 6:795–800
3. Van Cutsem E, Nordlinger B, Cervantes A (2010) Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol 21:93–97
4. National Comprehensive Cancer Network (2012) NCCN guidelines for: colon cancer (version 3.2012). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed April 2012
5. Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048
6. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664
7. Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605–3616
8. Carmichael J, Popiela T, Radstone D et al (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617–3627
9. Shirao K, Hoff PM, Ohtsu A et al (2004) Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 22:3466–3474
10. Diaz-Rubio E, Sastre J, Abad A, et al (1999) UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. Oncology 13(suppl. 3):35–40
11. Hochster HS, Luo W, Elizabeta C et al (2007) Phase II study of uracil-tegafur with leucovorin in elderly (≥75 years old) patients with colorectal cancer: ECOG 1299. J Clin Oncol 25:3523–3529
12. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
13. Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181
14. Price TJ, Zannino D, Wilson K (2012) Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann Oncol 23:1531–1536
15. Seymour MT, Thompson CL, Wasan H et al (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377:1749–1759
16. Peuguniez C, Fouriner C, Guerin-Meyer C et al (2011) A randomized cross-over trial comparing single-agents Capecitabine (C) and UFT plus leucovorin (LV) in patients with advanced colorectal cancer (CRC): final analysis of a patients preference study. J Clin Oncol 29 suppl 4;abstr 558
17. Hyodo I, Shirao K, Doi T et al (2006) A phase II study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 6(7):410–417
18. Kumar R, Jain K, Beeke C et al (2013) A population-based study of metastatic colorectal cancer in individuals aged ≥80 years. Cancer 119:722–728
19. Cunningham D, Lang I, Marcuello E et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14:1077–1085
20. Puthillath A, Mashtare T Jr, Wilding G et al (2009) A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. Crit Rev Oncol/Hematol 71:242–248
21. Feliu J, Safont J, Salud A et al (2010) Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer 102:1468–1473
22. Françoisa E, Guérinb O, Follana P et al (2011) Use of bevacizumab in elderly patients with metastatic colorectal cancer: review. J Geriatr Oncol 2:64–71